Question 1

What is the catalog number for Atosiban Impurity 34?

Accepted Answer

The catalog number for Atosiban Impurity 34 is RM-A201934.

Question 2

What sizes are available for Atosiban Impurity 34?

Accepted Answer

Atosiban Impurity 34 is available in the following size(s): 10 mg, 100 mg, 25 mg, 50 mg.

Question 3

How many pack sizes does Atosiban Impurity 34 come in?

Accepted Answer

Atosiban Impurity 34 is available in 4 different pack sizes.

Question 4

Is Atosiban Impurity 34 in stock?

Accepted Answer

Atosiban Impurity 34 is currently made to order / not held in immediate stock. Contact us for lead time.

Question 5

How long will it take to receive this product if it’s custom made?

Accepted Answer

Lead times depend on the product type: custom polyclonal antibodies typically take 12-14 weeks, monoclonal antibodies 15-17 weeks, made-to-order recombinant proteins 4-8 weeks, and made-to-order recombinant antibodies 6-8 weeks. These are estimates and may shift due to production delays.

Question 6

What is the recommended dilution for this antibody?

Accepted Answer

A recommended dilution range for each validated application is provided on the datasheet, but optimal dilution should be titrated for your specific experimental system, sample type, and detection method.

Question 7

What is the recommended storage temperature after reconstitution?

Accepted Answer

Post-reconstitution storage guidance is listed on the datasheet, typically requiring aliquoting and storage at -20°C or -80°C to preserve activity.

Atosiban Impurity 34

Product Specifications

Synonyms

Molecular Formula

Molecular Weight

Target Alternative Name

Available Sizes

Frequently Asked Questions

Explore Other Products

Calcineurin B / PPP3R1 (BE2.1), CF647 conjugate, 0.1mg/mL

GSK3 alpha (GSK3A) pSer21 Rabbit Polyclonal Antibody

Bovine Protein C Receptor, Endothelial (PROCR) ELISA Kit

Bovine Protein C Receptor, Endothelial (PROCR) ELISA Kit

Human ERO1L (ERO1A) activation kit by CRISPRa

ADCY6 Human Gene Knockout Kit (CRISPR)